{"id":997629,"date":"2026-08-24T16:03:09","date_gmt":"2026-08-24T20:03:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\/"},"modified":"2026-08-24T16:03:09","modified_gmt":"2026-08-24T20:03:09","slug":"belite-bio-to-host-virtual-commercial-day-on-september-2-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\/","title":{"rendered":"Belite Bio to Host Virtual Commercial Day on September 2, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SAN DIEGO, Aug.  24, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vmxOMmwEElk1898Mtbk4nZFY2vLwB9DnyDrbmPnieW1aPScUsItNFM-tJdVMYDUXwwU6APOt0JwezkZoIfWMs_lDQGh8KBul_ouJTPN0MXTjcIRqbEGG93SoH9wrBy_-7sOu_quZ3bZFCnxPAvwF7tEBTs-Z8lfLvq3I72xvmIX3klNtWvIZbvgmUVD448kUQ-F8mEhic3h9qIjGq8ELzFnGrV70G9p_qEBJZ3WcMtoU_eWXvrZwwNDO0CiGPzkC3jIl1-Hbb8tVsS3MFhlcRTOi0eit-8-135cSMnplIs9n5H3e0j9_mUQX8oCc4t-6Kj5IEiJZTAkBUaZnx7Gv2vDVRgIIwV4LoaNzJYIRZEZgm4ux7gyRzgC4B3E22IDmuBPgClRuPAbT0-nW88sMmev3mWUb_S2vQlMVvi3E1Bw=\" rel=\"nofollow\" target=\"_blank\">Belite Bio<\/a>, Inc (NASDAQ: BLTE) (\u201cBelite Bio\u00ae\u201d or the \u201cCompany\u201d), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a Virtual Commercial Day on Wednesday, September 2, 2026, from 8:00 \u2013 9:30 a.m. ET.<\/p>\n<p>Belite Bio\u2019s management team will be joined by leading experts in ophthalmology and people living with Stargardt disease type 1 (STGD1), and will provide an overview of STGD1, the unmet need of people living with the disease, and the current treatment landscape. Management will also provide an update on the Company\u2019s prelaunch preparedness strategies and the potential commercial opportunity for tinlarebant in STGD1, if approved by the U.S. Food and Drug Administration (FDA).<\/p>\n<p>In August 2026, the FDA accepted and granted Priority Review designation of the New Drug Application for tinlarebant for the treatment of STGD1. The FDA has set a Prescription Drug User Fee Act date of February 12, 2027.<\/p>\n<p>\n        <strong>Webcast Information<\/strong><br \/>\n        <br \/>\n        <strong>Date:\u00a0<\/strong>Wednesday, September 2, 2026<br \/><strong>Time:\u00a0<\/strong>8:00 a.m. Eastern Time (5:00 a.m. Pacific Time)<br \/><strong>Webcast Link:\u00a0<\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lYr_0-ngEAhVLv1plMjtI5GOegy5LSjplsAK9cIBz5KgNuqEI09KR4eVzVY05ZZYkTHrNPXyeSTI4viUaba9fwVDexPp4NVB89tMw-edkOceuWNtC_of0e6vbDhoWni4QHH4LxfyZXTJmvmjb7pzgaAkeE5yuKBb9CNGRfmFHO0=\" rel=\"nofollow\" target=\"_blank\">https:\/\/events.q4inc.com\/attendee\/785241581<\/a><\/p>\n<p>\n        <strong>Webcast Link Instructions<\/strong><br \/>\n        <br \/>A webcast of the event can be accessed and a replay will be archived under &#8220;Events&#8221; in the investor relations section of the Belite Bio website at:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lYr_0-ngEAhVLv1plMjtI4zVILVVYKTKBjCZtNWbp98X-pk08vz084ZnJUpnpNCFLyiOUDa6UzxRuuYeS5eZGYK7CS8EVD2S-bdtT2gqjKGROmnxKwr0_ywcG-NJQ7elLheozaRC7EisGtEbnIk33rfGG8baNHrDUBxCcJd67yoLhJwSMjxFjxwj8DxRWUQof56GKEUi97hQ837bZra6CqhQJiVQrcBkVL_yJo3cze22DJNAmWydD_yid83Hr6Z01J88xSkjYAcEh5T1tWISL5hqL5xQh1NcrscrV1br8smV7V0x_0TiE9yQ885DUzBlSOOrCoP0I0opp88XC3Cfl7OwJSlWpZd-OqfTKuGseZFpFPfi_Qb4YKwO0MK90JB-Ce-22RwCmicWBpOoqcODZL_NK6PnLX9o2ckrprB7cPoGiGbx20XlttjEwzioPzpF1S7ajI8geh3TPWvD6OE7AQ==\" rel=\"nofollow\" target=\"_blank\">https:\/\/investors.belitebio.com\/presentations-events\/events<\/a>.<\/p>\n<p>\n        <strong>About Belite Bio<\/strong><br \/>\n        <br \/>Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio\u2019s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent and adult subjects with STGD1, which met its primary endpoint, and the drug is currently being evaluated in a Phase 2\/3 trial (DRAGON II) in adolescent and adult subjects with STGD1 and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook, or visit us at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MG6mgGREjszYJHAezEzZHEy5297G1UqZ2GFtLAjM1ucaVsYbaN50Vz40LKy6E-kLQC9UDhmSM6VNtj_4dM4dWAKQpDhLY5SkGaNM4_Qv1cCIOe5UkhuyBFIvmWZTLiMiHjoU2iacwWiM46Wi3kLUSccoaUD-M3r6-Npa1_-B_Cfoed7yyjaDhOCxoOjYAQzFgx49kaE78PjeByTRJune-PKjAZjOH3aFniO-Q_2ZJ68_5AyOsLEzjiM4KbP4VqXpsF7x7hjs-yeXZl-JU3Nxlg==\" rel=\"nofollow\" target=\"_blank\">www.belitebio.com<\/a>.<\/p>\n<p>\n        <strong>Media and Investor Relations Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l2dpK2Qyj7rSL17v3VPFPjkN9c4jswc5CUyc9ac6olGRwix7X7xdb2JWdHUiMJqThtdmpoMfhCmVT4esQr9Q2VW8C0aEBizVg_PY8D6bQyM=\" rel=\"nofollow\" target=\"_blank\">ir@belitebio.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNTE1MiM3ODAwODE1IzIyMzM3MzI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OTZiMDI3MmUtMmM3YS00MzJlLTg4M2YtNDhlNDgwYWRjYmUyLTEyNDUyODUtMjAyNi0wOC0yNC1lbg==\/tiny\/Belite-Bio-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) &#8212; Belite Bio, Inc (NASDAQ: BLTE) (\u201cBelite Bio\u00ae\u201d or the \u201cCompany\u201d), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a Virtual Commercial Day on Wednesday, September 2, 2026, from 8:00 \u2013 9:30 a.m. ET. Belite Bio\u2019s management team will be joined by leading experts in ophthalmology and people living with Stargardt disease type 1 (STGD1), and will provide an overview of STGD1, the unmet need of people living with the disease, and the current treatment landscape. Management will also provide an update on the Company\u2019s prelaunch preparedness strategies and the potential commercial opportunity for tinlarebant &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Belite Bio to Host Virtual Commercial Day on September 2, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-997629","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Belite Bio to Host Virtual Commercial Day on September 2, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Belite Bio to Host Virtual Commercial Day on September 2, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) &#8212; Belite Bio, Inc (NASDAQ: BLTE) (\u201cBelite Bio\u00ae\u201d or the \u201cCompany\u201d), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a Virtual Commercial Day on Wednesday, September 2, 2026, from 8:00 \u2013 9:30 a.m. ET. Belite Bio\u2019s management team will be joined by leading experts in ophthalmology and people living with Stargardt disease type 1 (STGD1), and will provide an overview of STGD1, the unmet need of people living with the disease, and the current treatment landscape. Management will also provide an update on the Company\u2019s prelaunch preparedness strategies and the potential commercial opportunity for tinlarebant &hellip; Continue reading &quot;Belite Bio to Host Virtual Commercial Day on September 2, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-24T20:03:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNTE1MiM3ODAwODE1IzIyMzM3MzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Belite Bio to Host Virtual Commercial Day on September 2, 2026\",\"datePublished\":\"2026-08-24T20:03:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\\\/\"},\"wordCount\":375,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNTE1MiM3ODAwODE1IzIyMzM3MzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\\\/\",\"name\":\"Belite Bio to Host Virtual Commercial Day on September 2, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNTE1MiM3ODAwODE1IzIyMzM3MzI=\",\"datePublished\":\"2026-08-24T20:03:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNTE1MiM3ODAwODE1IzIyMzM3MzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNTE1MiM3ODAwODE1IzIyMzM3MzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Belite Bio to Host Virtual Commercial Day on September 2, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Belite Bio to Host Virtual Commercial Day on September 2, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\/","og_locale":"en_US","og_type":"article","og_title":"Belite Bio to Host Virtual Commercial Day on September 2, 2026 - Market Newsdesk","og_description":"SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) &#8212; Belite Bio, Inc (NASDAQ: BLTE) (\u201cBelite Bio\u00ae\u201d or the \u201cCompany\u201d), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a Virtual Commercial Day on Wednesday, September 2, 2026, from 8:00 \u2013 9:30 a.m. ET. Belite Bio\u2019s management team will be joined by leading experts in ophthalmology and people living with Stargardt disease type 1 (STGD1), and will provide an overview of STGD1, the unmet need of people living with the disease, and the current treatment landscape. Management will also provide an update on the Company\u2019s prelaunch preparedness strategies and the potential commercial opportunity for tinlarebant &hellip; Continue reading \"Belite Bio to Host Virtual Commercial Day on September 2, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-24T20:03:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNTE1MiM3ODAwODE1IzIyMzM3MzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Belite Bio to Host Virtual Commercial Day on September 2, 2026","datePublished":"2026-08-24T20:03:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\/"},"wordCount":375,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNTE1MiM3ODAwODE1IzIyMzM3MzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\/","name":"Belite Bio to Host Virtual Commercial Day on September 2, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNTE1MiM3ODAwODE1IzIyMzM3MzI=","datePublished":"2026-08-24T20:03:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNTE1MiM3ODAwODE1IzIyMzM3MzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNTE1MiM3ODAwODE1IzIyMzM3MzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-to-host-virtual-commercial-day-on-september-2-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Belite Bio to Host Virtual Commercial Day on September 2, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/997629","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=997629"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/997629\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=997629"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=997629"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=997629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}